Rejoinder
From MaRDI portal
Recommendations
- Adaptive designs from the viewpoint of an academic biostatistician
- Methodological developments vs. regulatory requirements
- Opening the adaptive toolbox
- Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians
- FDA's critical path initiative: a perspective on contributions of biostatistics
Cited in
(16)- Ephedra
- Rejoinder
- Rejoinder
- Rejoinder
- FDA's critical path initiative: a perspective on contributions of biostatistics
- Adaptive designs from the viewpoint of an academic biostatistician
- Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians
- Opening the adaptive toolbox
- Methodological developments vs. regulatory requirements
- Rejoinder
- Rejoinder
- Rejoinder
- Rejoinder
- Rejoinder
- Rejoinder
- Rejoinder to Discussions on “Approval policies for modifications to machine learning‐based software as a medical device: A study of bio‐creep”
This page was built for publication: Rejoinder
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5122848)